pharmaceutical

Three healthcare stocks—Pfizer (6.5% yield), Medtronic (3.6% yield with 48-year dividend streak), and Omega Healthcare (5.8% yield)—offer retirees attractive income streams amid aging demographics.

Phoenix Asia Holdings ($PHOE) surged 47% after-hours following $1B deal to acquire ACEA Pharma, pivoting from construction into oncology and autoimmune drug development.

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion in all-cash deal, marking entry into U.S. market and strengthening rare disease focus.

Three dividend-yielding stocks face temporary challenges but offer strong fundamental value and 6.5-7% yields, positioning them for potential major rebounds.

Novo Nordisk's Q1 sales of $15.17B beat estimates, with Wegovy pill reaching 2M prescriptions. Company raised 2026 guidance to $42.39-$46.24B; shares surged 7.11%.

Novo Nordisk reported Q1 2026 adjusted operating profit of DKK 32.9B, raising 2026 guidance on Wegovy® pill's success with 2M total prescriptions since January launch.

Scilex's ACEA subsidiaries sell ACEA Pharma to Phoenix Asia Holdings for $1 billion in stock, with Nasdaq listing expected by Q2 2026.

Three dividend stocks—AbbVie (3.3%), Medtronic (3.6%), and Enbridge (5.2%)—create monthly income through staggered payments. Combined strategy offers consistent cash flow from financially strong healthcare and energy companies.

Pfizer beats Q1 2026 expectations with $0.75 EPS and $14.45B in sales. Patent settlement extends Vyndamax protection to June 2031, ensuring revenue stability.

AbbVie beats Q1 earnings with $15B revenue, accelerates $31B immunology drug guidance to 2026 from 2027. Stock down 10% YTD despite outperformance.

AbbVie, Verizon, and Canadian Natural Resources offer compelling dividend yields (3.4%-5.9%) with growth potential at low valuations heading into May 2026.

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.

Roche offers defensive 2026 portfolio appeal with 7% sales growth and 13% profit growth, emphasizing stability over explosive expansion through diversified healthcare exposure.

Bristol Myers Squibb surges 5% after beating Q1 earnings expectations, with growth portfolio sales up 12% and full-year guidance reaffirmed.

Bristol-Myers Squibb stock jumped 4.44% after Q1 earnings beat expectations, with revenue up 3% and growth portfolio surging 12% year-over-year.

Teva Pharmaceutical beats Q1 earnings expectations and announces $700M Emalex acquisition plus share buyback, signaling confidence in specialty drug strategy and cost-cutting targets.

Costco, Sanofi, and SAP announce double-digit dividend increases—13%, 19%, and 15% respectively—reflecting mega-cap confidence in cash generation and shareholder commitment.

Sun Pharma agrees to acquire Organon for $14/share in all-cash deal, sending shares up 16.87% as women's health firm finds exit after struggling 2021 Merck spinoff.

Eli Lilly's new weight-loss drug Foundayo recorded just 3,707 prescriptions in week two, trailing Novo Nordisk's Wegovy by over 400%, triggering a 4% stock decline.

Orion posts strong Q1 with 17.8% revenue growth, 47.3% operating profit surge, and raises 2026 outlook. Pipeline advances boost investor confidence.